Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $14
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $14.
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $14.